NCT05841186 Correlation of Timing of Pegfilgrastim Administration and PIBP.
| NCT ID | NCT05841186 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guangdong Provincial People's Hospital |
| Condition | Pegfilgrastim |
| Study Type | INTERVENTIONAL |
| Enrollment | 156 participants |
| Start Date | 2023-05-04 |
| Primary Completion | 2025-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 156 participants in total. It began in 2023-05-04 with a primary completion date of 2025-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
According to the National Comprehensive Cancer Network (NCCN) guidelines, patients receiving high-risk or moderate-risk febrile neutropenia (FN) chemotherapy with at least one risk factor should receive prophylactic granulocyte colony-stimulating factors (G-CSFs). However, pegfilgrastim-induced bone pain (PIBP) remains a common and significant clinical issue without a satisfactory solution. Studies have reported that the incidence rate of PIBP is 71.3%, with severe bone pain occurring in 27.0% of cases. Currently, the available data on PIBP treatment are limited to case reports, reviews, and small randomized controlled trials. The NCCN guidelines recommend preventive oral non-steroidal anti-inflammatory drugs or antihistamines as the treatment for PIBP. However, even with these preventive measures, the incidence rate of PIBP remains high at 61.1%, with severe bone pain occurring in 19.2% of cases. Severe bone pain can significantly impact the patient's health-related quality of life (HRQol), leading to potential refusal of pegfilgrastim administration and subsequent dose reduction in effective chemotherapy. Ultimately, this may have negative implications for tumor cure rates and patient survival. Based on previous literature, it appears that delaying the administration of pegfilgrastim may be associated with a lower incidence of PIBP. Therefore, our study aims to investigate the correlation between the timing of pegfilgrastim administration and the occurrence of PIBP.
Eligibility Criteria
Inclusion Criteria: 1. Age greater than or equal to 18 years and less than or equal to 70 years. 2. Pathologically or histologically confirmed diagnosis of primary breast cancer. 3. Able to receive the chemotherapy regimen as scheduled. 4. Able to understand Chinese and fill out the study-related questionnaires independently. 5. Given written informed consent. 6. There is no need to use prescription or over-the-counter drugs regularly because of pre-existing chronic pain. Exclusion Criteria: 1. Suffering from bone pain due to other diseases currently. 2. Allergy or contraindication to chemotherapeutic agents or pegfilgrastim. 3. Previous use of pegfilgrastim. 4. Previous received chemotherapy. 5. Pregnancy or breastfeeding. 6. Concurrently accompanied by other primary malignant tumors.
Contact & Investigator
Kun Wang, professor
PRINCIPAL INVESTIGATOR
Guangdong Provincial People's Hospital
Frequently Asked Questions
Who can join the NCT05841186 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 70 Years, studying Pegfilgrastim. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05841186 currently recruiting?
Yes, NCT05841186 is actively recruiting participants. Contact the research team at gzwangkun@126.com for enrollment information.
Where is the NCT05841186 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT05841186 clinical trial?
NCT05841186 is sponsored by Guangdong Provincial People's Hospital. The principal investigator is Kun Wang, professor at Guangdong Provincial People's Hospital. The trial plans to enroll 156 participants.